Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib + Ribociclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT07405801Phase 2Recruiting
- Sponsor
- Roche
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Inavolisib + Ribociclib + Fulvestrant with Placebo + Ribociclib + Fulvestrant (2 arms). Primary endpoint: Confirmed Objective Response Rate at 2 years. Started Apr 2026; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07405801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405801.